{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:27:26Z","timestamp":1782628046949,"version":"3.54.5"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11064-025-04607-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:09:53Z","timestamp":1762333793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Saroglitazar at the Crossroads of Metabolic and Neurodegenerative Disease: A Critical Review of the Hepato-Neuro Axis and Translational Horizons"],"prefix":"10.1007","volume":"50","author":[{"given":"Himanshu","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Vashisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-2774","authenticated-orcid":false,"given":"Shiv Kumar","family":"Kushawaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra Singh","family":"Ashawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpi","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"4607_CR1","doi-asserted-by":"publisher","unstructured":"Nichols E et al (2019) Global, regional, and national burden of Alzheimer's disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):88\u2013106. https:\/\/doi.org\/10.1016\/S1474-4422(18)30403-4","DOI":"10.1016\/S1474-4422(18)30403-4"},{"key":"4607_CR2","doi-asserted-by":"publisher","first-page":"628520","DOI":"10.3389\/fneur.2021.628520","volume":"12","author":"Y Xiang","year":"2021","unstructured":"Xiang Y et al (2021) Systematic review estimating the burden of dementia in the Latin America and Caribbean region: A bayesian approach. Front Neurol 12:628520. https:\/\/doi.org\/10.3389\/fneur.2021.628520","journal-title":"Front Neurol"},{"key":"4607_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2471\/BLT.13.118422","volume":"91","author":"A Mavrodaris","year":"2013","unstructured":"Mavrodaris A, Powell J, Thorogood M (2013) Prevalences of dementia and cognitive impairment among older people in sub-Saharan africa: a systematic review. Bull World Health Organ 91:773\u2013783","journal-title":"Bull World Health Organ"},{"issue":"1","key":"4607_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM et al (2016) Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"3","key":"4607_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united States. Gastroenterology 148(3):547\u2013555. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.039","journal-title":"Gastroenterology"},{"issue":"6","key":"4607_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease, or cirrhosis. Nat Reviews Gastroenterol Hepatol 10(6):330\u2013344. https:\/\/doi.org\/10.1038\/nrgastro.2013.41","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"4607_CR7","doi-asserted-by":"publisher","unstructured":"Colognesi M, Gabbia D, De Martin S, Biomedicines (2020) 8(7), 229. https:\/\/doi.org\/10.3390\/biomedicines8070229","DOI":"10.3390\/biomedicines8070229"},{"issue":"3\u20134","key":"4607_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000329956","volume":"37","author":"JR Vieira","year":"2011","unstructured":"Vieira JR et al (2011) The metabolic syndrome and cognitive performance: the Northern Manhattan study. Neuroepidemiology 37(3\u20134):153\u2013159. https:\/\/doi.org\/10.1159\/000329956","journal-title":"Neuroepidemiology"},{"issue":"9","key":"4607_CR9","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1161\/ATVBAHA.112.252759","volume":"32","author":"KF Yates","year":"2012","unstructured":"Yates KF et al (2012) Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol 32(9):2060\u20132067. https:\/\/doi.org\/10.1161\/ATVBAHA.112.252759","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4607_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40271-021-00504-2","volume":"14","author":"LC Doward","year":"2021","unstructured":"Doward LC et al (2021) Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient-Patient-Centered Outcomes Res 14:533\u2013543. https:\/\/doi.org\/10.1007\/s40271-021-00504-2","journal-title":"Patient-Patient-Centered Outcomes Res"},{"key":"4607_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-018-0029-z","volume":"2","author":"T Kennedy-Martin","year":"2018","unstructured":"Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E (2018) Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J Patient-Reported Outcomes 2:1\u201314. https:\/\/doi.org\/10.1186\/s41687-018-0029-z","journal-title":"J Patient-Reported Outcomes"},{"issue":"1","key":"4607_CR12","doi-asserted-by":"publisher","first-page":"12614","DOI":"10.1038\/s41598-022-16754-3","volume":"12","author":"S Kang","year":"2022","unstructured":"Kang S et al (2022) Associations between non-alcoholic fatty liver disease and cognitive impairment and the effect modification of inflammation. Sci Rep 12(1):12614. https:\/\/doi.org\/10.1038\/s41598-022-16754-3","journal-title":"Sci Rep"},{"issue":"1","key":"4607_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12877-021-02715-y","volume":"22","author":"ES George","year":"2022","unstructured":"George ES et al (2022) Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review. BMC Geriatr 22(1):47. https:\/\/doi.org\/10.1186\/s12877-021-02715-y","journal-title":"BMC Geriatr"},{"issue":"7","key":"4607_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.012","volume":"158","author":"N Gehrke","year":"2020","unstructured":"Gehrke N, Schattenberg JM (2020) Metabolic inflammation\u2014a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology 158(7):1929\u20131947 e1926. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.012","journal-title":"Gastroenterology"},{"issue":"2","key":"4607_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/13894501113149990199","volume":"15","author":"R Agrawal","year":"2014","unstructured":"Agrawal R (2014) The first approved agent in the glitazar\u2019s class: Saroglitazar. Curr Drug Targets 15(2):151\u2013155. https:\/\/doi.org\/10.2174\/13894501113149990199","journal-title":"Curr Drug Targets"},{"issue":"2","key":"4607_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.20510\/ijmspr\/2022\/v8\/i2\/120942","volume":"8","author":"NJ Joshi","year":"2022","unstructured":"Joshi NJ et al (2022) Effect of PPAR \u03b1\/\u03b3 agonist on behavioural alterations in 6-OHDA induced parkinson\u2019s disease. Int J Med Sci Pharma Res 8(2):24\u201328. https:\/\/doi.org\/10.20510\/ijmspr\/2022\/v8\/i2\/120942","journal-title":"Int J Med Sci Pharma Res"},{"issue":"5","key":"4607_CR17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/cbdd.14306","volume":"102","author":"R Bhatt","year":"2023","unstructured":"Bhatt R et al (2023) Neuroprotective potential of Saroglitazar in 6-OHDA-induced parkinson\u2019s disease in rats. Chem Biol Drug Des 102(5):955\u2013971. https:\/\/doi.org\/10.1111\/cbdd.14306","journal-title":"Chem Biol Drug Des"},{"key":"4607_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuro.2023.11.105","volume":"105","author":"MS Jakkamsetti","year":"2024","unstructured":"Jakkamsetti MS et al (2024) Saroglitazar, a PPAR \u03b1\/\u03b3 agonist, alleviates 3-Nitropropionic acid-induced neurotoxicity in rats: unveiling the underlying mechanisms. Neurotoxicology 105:131\u2013146. https:\/\/doi.org\/10.1016\/j.neuro.2023.11.105","journal-title":"Neurotoxicology"},{"issue":"19","key":"4607_CR19","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1021\/acschemneuro.4c00167","volume":"15","author":"SK Mishra","year":"2024","unstructured":"Mishra SK, Mishra V (2024) Saroglitazar enhances memory functions and adult neurogenesis via Up-Regulation of Wnt\/\u03b2 Catenin signaling in the rat model of dementia. ACS Chem Neurosci 15(19):3449\u20133458. https:\/\/doi.org\/10.1021\/acschemneuro.4c00167","journal-title":"ACS Chem Neurosci"},{"issue":"18","key":"4607_CR20","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1021\/acschemneuro.3c00320","volume":"14","author":"G Sandeep","year":"2023","unstructured":"Sandeep G et al (2023) Neuroprotective effect of Saroglitazar on scopolamine-induced alzheimer\u2019s in rats: insights into the underlying mechanisms. ACS Chem Neurosci 14(18):3444\u20133459. https:\/\/doi.org\/10.1021\/acschemneuro.3c00320","journal-title":"ACS Chem Neurosci"},{"key":"4607_CR21","unstructured":"Rewers A (2021) Acute metabolic complications in diabetes. 3rd edition, Review from the National Institute of diabetes and Digestive and Kidney Diseases(US), Europe PMC"},{"issue":"9","key":"4607_CR22","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s10620-021-06950-6","volume":"66","author":"C Labenz","year":"2021","unstructured":"Labenz C et al (2021) Incidence dementia in elderly patients with nonalcoholic fatty liver disease in Germany. Dig Dis Sci 66(9):3179\u20133185. https:\/\/doi.org\/10.1007\/s10620-021-06950-6","journal-title":"Dig Dis Sci"},{"issue":"3","key":"4607_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3350\/cmh.2021.0357","volume":"28","author":"S Jeong","year":"2022","unstructured":"Jeong S et al (2022) Association of non-alcoholic fatty liver disease with incident dementia later in life among elderly adults. Clin Mol Hepatol 28(3):510. https:\/\/doi.org\/10.3350\/cmh.2021.0357","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"4607_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.47102\/annals-acadmedsg.202379","volume":"52","author":"SH Yoo","year":"2023","unstructured":"Yoo SH et al (2023) Risk of dementia in the elderly with non-alcoholic fatty liver disease: A nested case-control study in the Republic of Korea. Ann Acad Med Singapore 52(11):570\u2013579. https:\/\/doi.org\/10.47102\/annals-acadmedsg.202379","journal-title":"Ann Acad Med Singapore"},{"key":"4607_CR25","doi-asserted-by":"publisher","first-page":"985109","DOI":"10.3389\/fnagi.2022.985109","volume":"14","author":"L Wang","year":"2022","unstructured":"Wang L, Sang B, Zheng Z (2022) Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Aging Neurosci 14:985109. https:\/\/doi.org\/10.3389\/fnagi.2022.985109","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"4607_CR26","doi-asserted-by":"publisher","first-page":"e2354546","DOI":"10.1016\/j.jhep.2020.07.037","volume":"7","author":"E Massaad","year":"2024","unstructured":"Massaad E, Kiapour A (2024) Long-term health outcomes of traumatic brain injury in veterans. JAMA Netw Open 7(2):e2354546\u2013e2354546. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.037","journal-title":"JAMA Netw Open"},{"key":"4607_CR27","doi-asserted-by":"publisher","first-page":"738835","DOI":"10.3389\/fmed.2021.738835","volume":"8","author":"Q Liu","year":"2022","unstructured":"Liu Q et al (2022) Non-alcoholic fatty liver disease and longitudinal cognitive changes in middle-aged and elderly adults. Front Med 8:738835. https:\/\/doi.org\/10.3389\/fmed.2021.738835","journal-title":"Front Med"},{"key":"4607_CR28","doi-asserted-by":"publisher","unstructured":"Basit AT et al (2025) Amyloid solutions: Lecanemab, gantenerumab, and Donanemab in the treatment of alzheimer\u2019s disease. https:\/\/doi.org\/10.1186\/s41983-025-00968-3","DOI":"10.1186\/s41983-025-00968-3"},{"issue":"13","key":"4607_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/diagnostics13132254","volume":"13","author":"PF H\u00f8ilund-Carlsen","year":"2023","unstructured":"H\u00f8ilund-Carlsen PF et al (2023) FDG-PET versus amyloid-PET imaging for diagnosis and response evaluation in alzheimer\u2019s disease: benefits and pitfalls. Diagnostics 13(13):2254. https:\/\/doi.org\/10.3390\/diagnostics13132254","journal-title":"Diagnostics"},{"key":"4607_CR30","doi-asserted-by":"crossref","unstructured":"Sridhar GR (2021) Acetylcholinesterase inhibitors (galantamine, rivastigmine, and donepezil). NeuroPsychopharmacotherapy, pp 1\u201313","DOI":"10.1007\/978-3-319-56015-1_418-1"},{"issue":"33","key":"4607_CR31","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.2174\/1381612825666190808120947","volume":"25","author":"MT Kabir","year":"2019","unstructured":"Kabir MT et al (2019) Cholinesterase inhibitors for alzheimer\u2019s disease: multitargeting strategy based on anti-Alzheimer\u2019s drugs repositioning. Curr Pharm Design 25(33):3519\u20133535. https:\/\/doi.org\/10.2174\/1381612825666190808120947","journal-title":"Curr Pharm Design"},{"key":"4607_CR32","doi-asserted-by":"crossref","unstructured":"Timmins P (2024) Industry update: the latest developments in the field of therapeutic delivery, July 2024. In: Taylor & Francis","DOI":"10.1080\/20415990.2024.2414732"},{"issue":"16","key":"4607_CR33","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1039\/D3RA08333K","volume":"14","author":"AE Abdallah","year":"2024","unstructured":"Abdallah AE (2024) Review on anti-Alzheimer\u2019s drug development: Approaches, challenges and perspectives. RSC Adv 14(16):11057\u201311088. https:\/\/doi.org\/10.1039\/D3RA08333K","journal-title":"RSC Adv"},{"issue":"11","key":"4607_CR34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2174\/1389450123666220225101117","volume":"23","author":"Y Dai","year":"2022","unstructured":"Dai Y et al (2022) Amyloid-beta targeted therapeutic approaches for alzheimer\u2019s disease: a long road ahead. Curr Drug Targets 23(11):1040\u20131056. https:\/\/doi.org\/10.2174\/1389450123666220225101117","journal-title":"Curr Drug Targets"},{"issue":"1","key":"4607_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/receptors4010002","volume":"4","author":"LC Teixeira","year":"2025","unstructured":"Teixeira LC et al (2025) Exploring the role of GLP-1 receptor agonists in alzheimer\u2019s disease: A review of preclinical and clinical evidence. Receptors 4(1):2","journal-title":"Receptors"},{"issue":"6","key":"4607_CR36","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/02699052.2020.1721313","volume":"39","author":"MK Mahapatra","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM (2022) Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis, and neurodegenerative diseases: A narrative review. Pharm Res 39(6):1233\u20131248. https:\/\/doi.org\/10.1080\/02699052.2020.1721313","journal-title":"Pharm Res"},{"issue":"6","key":"4607_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1517\/13543784.2015.1021919","volume":"24","author":"Y Xiong","year":"2015","unstructured":"Xiong Y et al (2015) Investigational agents for the treatment of traumatic brain injury. Expert Opin Investig Drugs 24(6):743\u2013760. https:\/\/doi.org\/10.1517\/13543784.2015.1021919","journal-title":"Expert Opin Investig Drugs"},{"key":"4607_CR38","unstructured":"Ferguson LB (2018) Alcohol use disorders: Transcriptomic and bioinformatic approaches. Dissertation, The University of Texas at Austin, 2018"},{"issue":"3","key":"4607_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/02699052.2020.1723697","volume":"34","author":"HM Ma","year":"2020","unstructured":"Ma HM, Zafonte RD (2020) Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Injury 34(3):299\u2013315","journal-title":"Brain Injury"},{"issue":"10","key":"4607_CR40","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/10600280211009572","volume":"55","author":"S Kakehi","year":"2021","unstructured":"Kakehi S, Tompkins DM (2021) A review of Pharmacologic neurostimulant use during rehabilitation and recovery after brain injury. Ann Pharmacother 55(10):1254\u20131266. https:\/\/doi.org\/10.1177\/10600280211009572","journal-title":"Ann Pharmacother"},{"issue":"7","key":"4607_CR41","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/biomedicines12071558","volume":"12","author":"A Dekundy","year":"2024","unstructured":"Dekundy A et al (2024) Amantadine for traumatic brain injury\u2014Supporting evidence and mode of action. Biomedicines 12(7):1558. https:\/\/doi.org\/10.3390\/biomedicines12071558","journal-title":"Biomedicines"},{"key":"4607_CR42","doi-asserted-by":"publisher","unstructured":"Karamian A, Farzaneh H, Taheri M, Seifi A (2024) Effectiveness of Levetiracetam versus phenytoin in preventing seizure in traumatic brain injury patients: A systematic review and meta-analysis. Clin Neurol Neurosurg 108251. https:\/\/doi.org\/10.1016\/j.clineuro.2024.108251","DOI":"10.1016\/j.clineuro.2024.108251"},{"key":"4607_CR43","doi-asserted-by":"publisher","first-page":"612073","DOI":"10.3389\/fnmol.2021.612073","volume":"14","author":"S Sharma","year":"2021","unstructured":"Sharma S et al (2021) Neuropathophysiological mechanisms and treatment strategies for post-traumatic epilepsy. Front Mol Neurosci 14:612073. https:\/\/doi.org\/10.3389\/fnmol.2021.612073","journal-title":"Front Mol Neurosci"},{"key":"4607_CR44","doi-asserted-by":"publisher","unstructured":"Matta SE et al (2024) Pharmacologic management of the sequelae of traumatic brain Injuries. The primary care companion for CNS disorders. 26(4):56086. https:\/\/doi.org\/10.4088\/PCC.23f03670","DOI":"10.4088\/PCC.23f03670"},{"key":"4607_CR45","doi-asserted-by":"crossref","unstructured":"Sanshita RB et al (2023) Repurposing of Minocycline, a Tetracycline Antibiotic, for neurodegenerative disorders. Drug repurposing for emerging infectious diseases and cancer. Springer, pp 615\u2013654","DOI":"10.1007\/978-981-19-5399-6_27"},{"issue":"6","key":"4607_CR46","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.3390\/ijms24065250","volume":"24","author":"B Panizzutti","year":"2023","unstructured":"Panizzutti B et al (2023) Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis. Int J Mol Sci 24(6):5250. https:\/\/doi.org\/10.3390\/ijms24065250","journal-title":"Int J Mol Sci"},{"key":"4607_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00858-5","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Metformin attenuates plaque-associated Tau pathology and reduces amyloid-\u03b2 burden in APP\/PS1 mice. Alzheimers Res Ther 13:1\u201313. https:\/\/doi.org\/10.1186\/s13195-021-00858-5","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"4607_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-025-01672-3","volume":"17","author":"Y Shen","year":"2025","unstructured":"Shen Y et al (2025) CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in alzheimer\u2019s disease mice. Alzheimers Res Ther 17(1):20","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"4607_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/biomedicines8120589","volume":"8","author":"LR Wong","year":"2020","unstructured":"Wong LR, Wong P, Ho PCL (2020) Metabolic profiling of female tg2576 mouse brains provides novel evidence supporting intranasal low-dose Pioglitazone for long-term treatment at an early stage of alzheimer\u2019s disease. Biomedicines 8(12):589. https:\/\/doi.org\/10.3390\/biomedicines8120589","journal-title":"Biomedicines"},{"key":"4607_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-9-62","volume":"9","author":"MT Ferretti","year":"2012","unstructured":"Ferretti MT et al (2012) Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a Transgenic model of alzheimer\u2019s disease-like amyloid pathology. J Neuroinflamm 9:1\u201316. https:\/\/doi.org\/10.1186\/1742-2094-9-62","journal-title":"J Neuroinflamm"},{"issue":"1","key":"4607_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12986-024-00792-1","volume":"21","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A, Abutalebian F (2024) Unraveling the therapeutic efficacy of Resveratrol in alzheimer\u2019s disease: an umbrella review of systematic evidence. Nutr Metabolism 21(1):15. https:\/\/doi.org\/10.1186\/s12986-024-00792-1","journal-title":"Nutr Metabolism"},{"issue":"8","key":"4607_CR52","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00018-022-04363-4","volume":"79","author":"J Companys-Alemany","year":"2022","unstructured":"Companys-Alemany J et al (2022) NMDA receptor antagonists reduce amyloid-\u03b2 deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice. Cell Mol Life Sci 79(8):408. https:\/\/doi.org\/10.1007\/s00018-022-04363-4","journal-title":"Cell Mol Life Sci"},{"key":"4607_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11571-020-09592-8","volume":"14","author":"H Lv","year":"2020","unstructured":"Lv H et al (2020) Intranasal insulin administration May be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance. Cogn Neurodyn 14:323\u2013338. https:\/\/doi.org\/10.1007\/s11571-020-09592-8","journal-title":"Cogn Neurodyn"},{"issue":"1","key":"4607_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40478-021-01300-1","volume":"10","author":"M Celorrio","year":"2022","unstructured":"Celorrio M et al (2022) Acute Minocycline administration reduces brain injury and improves long-term functional outcomes after delayed hypoxemia following traumatic brain injury. Acta Neuropathol Commun 10(1):10. https:\/\/doi.org\/10.1186\/s40478-021-01300-1","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4607_CR55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0006-8993(01)02617-8","volume":"911","author":"VLR Rao","year":"2001","unstructured":"Rao VLR et al (2001) Neuroprotection by memantine, a non-competitive NMDA receptor antagonist, after traumatic brain injury in rats. Brain Res 911(1):96\u2013100. https:\/\/doi.org\/10.1016\/S0006-8993(01)02617-8","journal-title":"Brain Res"},{"issue":"2","key":"4607_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/fcp.14","volume":"38","author":"M Golmohammadi","year":"2024","unstructured":"Golmohammadi M et al (2024) Neuroprotective effects of riluzole in alzheimer\u2019s disease: A comprehensive review. Fundam Clin Pharmacol 38(2):225\u2013237. https:\/\/doi.org\/10.1111\/fcp.14","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"4607_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.taap.2015.01.014","volume":"283","author":"LJ Chen","year":"2015","unstructured":"Chen LJ et al (2015) Bleomycin induced epithelial\u2013mesenchymal transition (EMT) in pleural mesothelial cells. Toxicol Appl Pharmcol 283(2):75\u201382. https:\/\/doi.org\/10.1016\/j.taap.2015.01.014","journal-title":"Toxicol Appl Pharmcol"},{"key":"4607_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2023.01.021","volume":"207","author":"ZY Liu","year":"2023","unstructured":"Liu ZY et al (2023) Glycolytic reprogramming in organ fibrosis: new dynamics of the epigenetic landscape. Free Radic Biol Med 207:1\u201310. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.01.021","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"4607_CR59","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/nu17111797","volume":"17","author":"H George","year":"2025","unstructured":"George H et al (2025) Cultural and molecular factors predisposed to Non-Alcoholic fatty liver disease and type 2. Diabetes Mellitus Nutrients 17(11):1797. https:\/\/doi.org\/10.3390\/nu17111797","journal-title":"Diabetes Mellitus Nutrients"},{"key":"4607_CR60","doi-asserted-by":"publisher","unstructured":"Engin A (2017) Non-alcoholic fatty liver disease. Obes Lipotoxicity 443\u2013467. https:\/\/doi.org\/10.1007\/978-3-319-48382-5_18","DOI":"10.1007\/978-3-319-48382-5_18"},{"issue":"5","key":"4607_CR61","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/medicina58050641","volume":"58","author":"M Petrescu","year":"2022","unstructured":"Petrescu M et al (2022) Chronic inflammation\u2014A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina 58(5):641. https:\/\/doi.org\/10.3390\/medicina58050641","journal-title":"Medicina"},{"issue":"4","key":"4607_CR62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11154-024-09884-y","volume":"25","author":"A Ullah","year":"2024","unstructured":"Ullah A et al (2024) Pro-and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases). Reviews Endocr Metabolic Disorders 25(4):783\u2013803","journal-title":"Reviews Endocr Metabolic Disorders"},{"key":"4607_CR63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","volume":"38","author":"Y Serlin","year":"2015","unstructured":"Serlin Y, al (2015) Anatomy and physiology of the blood\u2013brain barrier. Semin Cell Dev Biol 38:2\u20136","journal-title":"Semin Cell Dev Biol"},{"key":"4607_CR64","doi-asserted-by":"crossref","unstructured":"Singh V, Sethi AK, Rath S, Mishra VN (2025) Synaptic plasticity and neuroinflammation: A therapeutic approach to neurological illnesses. Synaptic plasticity in neurodegenerative disorders. CRC, pp 93\u2013114","DOI":"10.1201\/9781003464648-7"},{"key":"4607_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-01757-6","volume":"17","author":"X Liu","year":"2020","unstructured":"Liu X et al (2020) The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. J Neuroinflamm 17:1\u201317. https:\/\/doi.org\/10.1186\/s12974-020-01757-6","journal-title":"J Neuroinflamm"},{"issue":"4","key":"4607_CR66","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"R Rajmohan","year":"2017","unstructured":"Rajmohan R, Reddy PH (2017) Amyloid-beta and phosphorylated Tau accumulations cause abnormalities at synapses of alzheimer\u2019s disease neurons. J Alzheimer\u2019s Disease 57(4):975\u2013999","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"3","key":"4607_CR67","doi-asserted-by":"publisher","first-page":"e01235","DOI":"10.1002\/brb3.1235","volume":"9","author":"JY Joung","year":"2019","unstructured":"Joung JY et al (2019) A literature review for the mechanisms of stress-induced liver injury. Brain Behav 9(3):e01235. https:\/\/doi.org\/10.1002\/brb3.1235","journal-title":"Brain Behav"},{"key":"4607_CR68","unstructured":"Friedman LS, Martin P (2017) Handbook of liver disease E-Book. Elsevier Health Sciences"},{"issue":"2","key":"4607_CR69","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11095-022-03271-2","volume":"74","author":"R Manco","year":"2021","unstructured":"Manco R, Itzkovitz S (2021) Liver zonation. J Hepatol 74(2):466\u2013468. https:\/\/doi.org\/10.1007\/s11095-022-03271-2","journal-title":"J Hepatol"},{"key":"4607_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","volume":"70","author":"M Del Giudice","year":"2018","unstructured":"Del Giudice M, Gangestad SW (2018) Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun 70:61\u201375","journal-title":"Brain Behav Immun"},{"issue":"1","key":"4607_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS et al (2021) Aldosterone, inflammation, the immune system, and hypertension. Am J Hypertens 34(1):15\u201327","journal-title":"Am J Hypertens"},{"issue":"2","key":"4607_CR72","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/ijms24021422","volume":"24","author":"ME Casado","year":"2023","unstructured":"Casado ME et al (2023) Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies. Int J Mol Sci 24(2):1422. https:\/\/doi.org\/10.3390\/ijms24021422","journal-title":"Int J Mol Sci"},{"key":"4607_CR73","doi-asserted-by":"publisher","unstructured":"Engin A (2017) Diet-induced obesity and the mechanism of leptin resistance. Obes Lipotoxicity 381\u2013397. https:\/\/doi.org\/10.1007\/978-3-319-48382-5_17","DOI":"10.1007\/978-3-319-48382-5_17"},{"issue":"11","key":"4607_CR74","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1007\/s00210-024-02000-1","volume":"397","author":"SM Firdous","year":"2024","unstructured":"Firdous SM, Khan SA, Maity A (2024) Oxidative stress\u2013mediated neuroinflammation in alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 397(11):8189\u20138209. https:\/\/doi.org\/10.1007\/s00210-024-02000-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4607_CR75","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.arr.2022.101619","volume":"77","author":"R Bai","year":"2022","unstructured":"Bai R et al (2022) Oxidative stress: the core pathogenesis and mechanism of alzheimer\u2019s disease. Ageing Res Rev 77:101619. https:\/\/doi.org\/10.1016\/j.arr.2022.101619","journal-title":"Ageing Res Rev"},{"key":"4607_CR76","doi-asserted-by":"publisher","first-page":"1494560","DOI":"10.3389\/fendo.2024.1494560","volume":"15","author":"YH Fan","year":"2025","unstructured":"Fan YH et al (2025) Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease. Front Endocrinol 15:1494560. https:\/\/doi.org\/10.3389\/fendo.2024.1494560","journal-title":"Front Endocrinol"},{"key":"4607_CR77","doi-asserted-by":"publisher","unstructured":"Ezhilarasan D, Metabolism (2024) 155912. https:\/\/doi.org\/10.1016\/j.metabol.2024.155912","DOI":"10.1016\/j.metabol.2024.155912"},{"issue":"40","key":"4607_CR78","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.2174\/1381612825666190115121018","volume":"24","author":"RRG Wadhwa","year":"2018","unstructured":"Wadhwa RRG, Maurya PK (2018) Oxidative stress and accelerated aging in neurodegenerative and neuropsychiatric disorders. Curr Pharm Design 24(40):4711\u20134725","journal-title":"Curr Pharm Design"},{"key":"4607_CR79","unstructured":"Nuamah MF (2022) The study of troglitazone liver toxicity via in vitro and in Silico approaches. University of Nottingham"},{"key":"4607_CR80","doi-asserted-by":"publisher","first-page":"119191","DOI":"10.1016\/j.lfs.2021.119191","volume":"271","author":"RN Dharavath","year":"2021","unstructured":"Dharavath RN et al (2021) Saroglitazar, a novel dual PPAR-\u03b1\/\u03b3 agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL\/6J male mice. Life Sci 271:119191. https:\/\/doi.org\/10.1016\/j.lfs.2021.119191","journal-title":"Life Sci"},{"key":"4607_CR81","doi-asserted-by":"crossref","unstructured":"Windon C, Elahi FM (2024) Vascular cognitive Impairment, in ischemic stroke therapeutics: A comprehensive guide. Springer, pp 399\u2013424","DOI":"10.1007\/978-3-031-49963-0_30"},{"key":"4607_CR82","doi-asserted-by":"crossref","unstructured":"Shen J et al (2024) The role of T-lymphocytes in central nervous system diseases. Brain Res Bull, 110904","DOI":"10.1016\/j.brainresbull.2024.110904"},{"key":"4607_CR83","unstructured":"Korat NJ (2018) Pharmacological evaluation of Gallic Acid and Saroglitazar against experimentally induced Alzheimer\u2019s disease model in rats. Dissertation, Institute of Pharmacy, Nirma University, Ahmedabad"},{"issue":"16","key":"4607_CR84","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.3390\/ijms22168876","volume":"22","author":"P Layrolle","year":"2021","unstructured":"Layrolle P et al (2021) PPAR gamma and viral infections of the brain. Int J Mol Sci 22(16):8876. https:\/\/doi.org\/10.3390\/ijms22168876","journal-title":"Int J Mol Sci"},{"key":"4607_CR85","doi-asserted-by":"publisher","unstructured":"Palafox-S\u00e1nchez V et al (2021) The interaction between the brain and liver regulates lipid metabolism in the TBI pathology. Biochimica et biophysica acta (BBA)-Molecular basis of disease. 1867(4):166078. https:\/\/doi.org\/10.1016\/j.bbadis.2021.166078","DOI":"10.1016\/j.bbadis.2021.166078"},{"issue":"1","key":"4607_CR86","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.4110\/in.2025.25.e10","volume":"25","author":"HK Shin","year":"2025","unstructured":"Shin HK, Bang YJ (2025) Aromatic amino acid metabolites: molecular messengers bridging immune-microbiota communication. Immune Netw 25(1):e10","journal-title":"Immune Netw"},{"issue":"2","key":"4607_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/biomedicines10020249","volume":"10","author":"A Tripodi","year":"2022","unstructured":"Tripodi A, Lombardi R, Primignani et al (2022) Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): causes and consequences. Biomedicines 10(2):249. https:\/\/doi.org\/10.3390\/biomedicines10020249","journal-title":"Biomedicines"},{"key":"4607_CR88","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.atherosclerosis.2019.05.077","volume":"287","author":"M Krishnappa","year":"2019","unstructured":"Krishnappa M et al (2019) Saroglitazar reduces predictive lipid biomarkers of cardiovascular diseases. Atherosclerosis 287:e35. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.05.077","journal-title":"Atherosclerosis"},{"issue":"21","key":"4607_CR89","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.3390\/ijms222111677","volume":"22","author":"GA Czapski","year":"2021","unstructured":"Czapski GA, Strosznajder JB (2021) Glutamate and GABA in microglia-neuron cross-talk in alzheimer\u2019s disease. Int J Mol Sci 22(21):11677","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4607_CR90","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13041-019-0525-5","volume":"12","author":"LJ Jia","year":"2019","unstructured":"Jia LJ, Pi\u00f1a-Crespo, Li Y (2019) Restoring Wnt\/\u03b2-catenin signaling is a promising therapeutic strategy for alzheimer\u2019s disease. Mol Brain 12(1):104","journal-title":"Mol Brain"},{"issue":"2","key":"4607_CR91","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jceh.2021.10.001","volume":"12","author":"P Padole","year":"2022","unstructured":"Padole P et al (2022) Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients. J Clin Experimental Hepatol 12(2):435\u2013439. https:\/\/doi.org\/10.1016\/j.jceh.2021.10.001","journal-title":"J Clin Experimental Hepatol"},{"issue":"7","key":"4607_CR92","first-page":"827","volume":"25","author":"S Nabi","year":"2022","unstructured":"Nabi S, Bhandari U, Haque SE (2022) Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: plausible role of NLRP3 inflammasome and NF-\u03baB. Iran J Basic Med Sci 25(7):827","journal-title":"Iran J Basic Med Sci"},{"issue":"23","key":"4607_CR93","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3390\/cells11233781","volume":"11","author":"L Wang","year":"2022","unstructured":"Wang L et al (2022) Progress in research on TLR4-mediated inflammatory response mechanisms in brain injury after subarachnoid hemorrhage. Cells 11(23):3781. https:\/\/doi.org\/10.3390\/cells11233781","journal-title":"Cells"},{"key":"4607_CR94","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s10753-019-00967-6","volume":"42","author":"NF Hassan","year":"2019","unstructured":"Hassan NF et al (2019) Saroglitazar deactivates the hepatic LPS\/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion\/LPS model-induced non-alcoholic steatohepatitis. Inflammation 42:1056\u20131070","journal-title":"Inflammation"},{"key":"4607_CR95","doi-asserted-by":"publisher","first-page":"109688","DOI":"10.1016\/j.intimp.2023.109688","volume":"115","author":"MR Francis","year":"2023","unstructured":"Francis MR, El-Sheakh AR, Suddek GM (2023) Saroglitazar, a dual PPAR-\u03b1\/\u03b3 agonist, alleviates LPS-induced hepatic and renal injury in rats. Int Immunopharmacol 115:109688","journal-title":"Int Immunopharmacol"},{"issue":"S2","key":"4607_CR96","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/trf.15171","volume":"59","author":"PA Abdelmalik","year":"2019","unstructured":"Abdelmalik PA, Draghic N, Ling GS (2019) Management of moderate and severe traumatic brain injury. Transfusion 59(S2):1529\u20131538","journal-title":"Transfusion"},{"issue":"16","key":"4607_CR97","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.3390\/ijms22168876","volume":"22","author":"P Layrolle","year":"2021","unstructured":"Layrolle P, Payoux P, Chavanas S (2021) PPAR gamma and viral infections of the brain. Int J Mol Sci 22(16):8876","journal-title":"Int J Mol Sci"},{"key":"4607_CR98","doi-asserted-by":"crossref","unstructured":"Kelty TJ et al (2023) Emerging links between nonalcoholic fatty liver disease and neurodegeneration. Seminars in liver disease. Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-0043-1762585"},{"issue":"5","key":"4607_CR99","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/ph18050657","volume":"18","author":"DM Al-Nouri","year":"2025","unstructured":"Al-Nouri DM (2025) Unlocking the neuroprotective effect of Quercetin against Cadmium-Induced hippocampal damage in rats: PPAR\u03b3 activation as a key mechanism. Pharmaceuticals 18(5):657","journal-title":"Pharmaceuticals"},{"key":"4607_CR100","unstructured":"Fiaschini N (2021) The role of intestinal inflammation on the gut-liver axis. Dissertation, Universit\u00e0 degli Studi di Roma La Sapienza"},{"key":"4607_CR101","doi-asserted-by":"crossref","unstructured":"Cacabelos R et al (2022) Pharmacogenomics of alzheimer\u2019s disease: novel strategies for drug utilization and development. Pharmacogenomics in drug discovery and development. Springer, pp 275\u2013387","DOI":"10.1007\/978-1-0716-2573-6_13"},{"issue":"18","key":"4607_CR102","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/nu16183061","volume":"16","author":"H Yuan","year":"2024","unstructured":"Yuan H et al (2024) Biomarkers for health functional foods in metabolic dysfunction-associated steatotic liver disorder (MASLD) prevention: an integrative analysis of network pharmacology, gut microbiota, and multi-omics. Nutrients 16(18):3061","journal-title":"Nutrients"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04607-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:06:01Z","timestamp":1764738361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04607-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4607"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04607-4","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"348"}}